Trinity compound research profile
Cerebrolysin
A peptide and amino-acid preparation studied in neurological recovery, neuroprotection, cognition, and neuroplasticity research.
Research overview
Cerebrolysin is an injectable preparation containing low-molecular-weight peptides and amino acids derived from purified porcine brain proteins. It has been studied internationally in neurological research involving stroke recovery, brain injury, cognition, and neuroplasticity.
Published findings vary by indication and study design, so evidence quality and limitations are important parts of any review. Trinity’s Advanced Research Search should be used for the detailed source-backed summary.
Human evidence summary
There have been many human studies, but the overall picture is mixed and leans unfavorable. A major independent review of all the best-quality stroke studies (called a Cochrane review) found no real evidence that it helps reduce death or disability after a stroke (Cochrane review). However, one specific trial (called CARS) did find improved arm/hand movement recovery when given early after a stroke (study), and a separate analysis combining 9 trials found some positive trend (analysis). So the honest picture is: some individual studies look promising, but when all the best evidence is combined, it doesn't clearly prove the drug works, and there are concerns about study quality and where these positive studies were done.
Preclinical evidence summary
The existing profile data does not detail specific animal studies for Cerebrolysin — the evidence base described is centered on human clinical trials, given the extensive human trial history for stroke, dementia, and brain injury.
Source material
Use the linked publications and records to evaluate study design, population, limitations, and relevance.